MARKET

GRTX

GRTX

GALERA THERAPEUTICS, INC.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.46
-0.13
-1.23%
After Hours: 10.46 0 0.00% 16:00 05/29 EDT
OPEN
10.61
PREV CLOSE
10.59
HIGH
10.72
LOW
10.45
VOLUME
14.25K
TURNOVER
--
52 WEEK HIGH
19.50
52 WEEK LOW
5.58
MARKET CAP
259.62M
P/E (TTM)
-3.9680
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average GRTX stock price target is 20.00 with a high estimate of 30.00 and a low estimate of 14.00.

EPS

GRTX News

More
Galera Therapeutics Announces Avasopasem Manganese Improved Markers of Chronic Kidney Disease in Patients Receiving Cisplatin
GlobeNewswire · 1d ago
Galera Therapeutics to Host Virtual KOL Event on Cisplatin-Induced Chronic Kidney Disease
Galera Therapeutics, Inc. (GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, announced today that it will host
GlobeNewswire · 05/18 20:05
Galera Therapeutics Highlights New Data From Phase 2b Trial For Avasopasem Manganese on Cisplatin-Induced Chronic Kidney Disease to Be Presented At ASCO May 29
Galera Therapeutics, Inc. (NASDAQ:GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform
Benzinga · 05/13 21:55
Galera Therapeutics Announces New Data from the Phase 2b Trial on the Effect of Avasopasem Manganese on Cisplatin-Induced Chronic Kidney Disease to be Presented at ASCO 2020 Virtual Scientific Program
Galera Therapeutics, Inc. (GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced a retrospective an
GlobeNewswire · 05/13 21:19
Galera Therapeutics Q1 EPS $(0.740)
Galera Therapeutics (NASDAQ:GRTX) reported quarterly losses of $(0.740) per share.
Benzinga · 05/12 11:04
Galera Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Updates
Galera Therapeutics, Inc. (GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results
GlobeNewswire · 05/12 11:00
Galera Therapeutics to Present at BofA Securities 2020 Health Care Conference
MALVERN, Pa., May 05, 2020 -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of.
GlobeNewswire · 05/05 12:00
U.S. IPO Week Ahead: GAN Bets On Itself In A One-IPO Week
Seeking Alpha - Article · 05/02 20:11

Industry

Biotechnology & Medical Research
+1.44%
Pharmaceuticals & Medical Research
+1.29%

Hot Stocks

Symbol
Price
%Change

About GRTX

Galera Therapeutics, Inc is a clinical stage biopharmaceutical company. It is focused on developing and commercializing a pipeline therapeutics to transform radiotherapy in cancer. It is focused on leveraging capability in superoxide dismutase mimetics to design drugs to reduce normal tissue toxicity from radiotherapy and to increase the anti-cancer efficacy of radiotherapy. Its pipeline product are GC4419 and GC4711. Its lead product candidate GC4419, is a potent selective small molecule dismutase mimetic. The Company is initially focused on developing GC4419 for the reduction of severe oral mucositis (SOM). GC4419, is also known as avasopasem manganese, and has completed two clinical trials. The Company’s second dismutase mimetic product candidate is GC4711. The Company is specifically targeting GC4711, an analog of GC4419, to increase the anti-cancer efficacy of SBRT. It is in Phase 1 development both as a lyophilized product for intravenous administration given as an oral capsule.
More

Webull offers kinds of Galera Therapeutics Inc stock information, including NASDAQ:GRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GRTX stock news, and many more online research tools to help you make informed decisions.